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ABSTRACT
INTRODUCTION Cigarette smoking is the most important risk factor for Crohn’s disease 
(CD). The effectiveness of smoking cessation programs (SCPs) in patients with 
CD is still poorly understood.
METHODS This was a retrospective, observational, single-centre, cohort study of 
136 active smokers with mean age 55 years (SD=11), 58% males, including 27 
(19.8%) patients with CD who entered the multidisciplinary SCP of the Luigi 
Sacco University Hospital of Milan from January 2017 through January 2019. A 
pulmonologist was responsible for the clinical and pharmacological management, 
while a psychiatrist and a psychologist conducted the counselling and assessed 
the motivation to quit, anxiety and depression using the Brief Psychiatric Rating 
Scale (BPRS) and the nicotine dependence with the Fagerström test. Patients 
were defined as quitters after 12 months.
RESULTS Demographic and clinical characteristics, and Fagerström score, did not 
differ in patients with and without CD. At baseline, patients with CD had a 
higher BPRS (median: 27, IQR: 22–32; vs 25 and 22–28.5; p=0.03), and a lower 
motivation to quit score (median: 10, IQR: 9–13; vs 14 and 12–15; p<0.001). After 
12 months, the quitting rate of smokers with CD was significantly lower (14.8% 
vs 36.7%; p<0.022) and the chance of quitting was negatively associated with the 
baseline BPRS (r=-0.256; p<0.003). Varenicline and nicotine replacement therapy 
tended to be less effective in patients with CD.
CONCLUSIONS The lower efficacy of SCPs in patients with CD might be secondary to 
a higher prevalence of anxiety and depression. Psychological issue recognition 
and support should be enhanced to increase SCP effectiveness in CD.
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INTRODUCTION
Crohn’s disease (CD) is a chronic idiopathic inflammatory 
bowel disease (IBD). Several factors have been 
implicated in the development of CD, including genetics 
and environmental exposure1. Cigarette smoking is the 
most important independent risk factor for CD, being 
associated with disease development, poorer prognosis, 
worse quality of life and increased rate of flare-ups 
and hospital admissions, as well as a higher need for 
corticosteroids and immunomodulators2-4. The risk of 
CD exacerbation has been found to be proportional 
to the number of cigarettes currently smoked by 
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patients5. Smokers also have a greater risk of perforating 
complications and fistulisation, of undergoing surgery 
and of recurrence after a surgery intervention6-11. A recent 
large observational study showed how a smoking habit in 
patients with CD is associated with higher corticosteroid 
burden, higher corticosteroid dependence and also a 
higher risk of intestinal surgery when compared with 
quitters12. 
The harmful effects of cigarette smoking can be 
explained by different pathogenetic processes, such 
as an intense release of inflammatory cytokines, 
with consequent immune cell recruitment, and the 
production of reactive oxygen species coupled with a 
lessened antioxidant capacity13.
Despite these premises, the percentage of smokers 
in patients with CD remains high, representing a 
consistent social and healthcare burden2; moreover, 
many of these patients still underestimate the link 
between smoking and disease worsening, which 
reduces the motivation to quit14,15.
Smoking cessation programs (SCPs), relying on 
both pharmacological therapy and psychological 
counselling (including group behavioural therapy) 
to improve motivation and coping skills, have been 
proven effective in increasing quitting rates in the 
general population16,17, with success rates ranging 
from 32% to 36%18 (with better results for inpatients19 
than for outpatients20), greatly surpassing cessation 
rates obtained via simple physician advice (3–6%)21. 
However, only limited data are available on the efficacy 
of SCPs in patients with CD2,5. Smoking cessation, 
being a disease modifier, represents an intervention 
of paramount importance in patients with CD, and 
should be considered a priority in all CD smokers4 as 
it may result in a significant improvement in disease 
activity, the need for surgery, and disease-related 
costs22. To date, however, available studies have 
shown low quit rates in smokers with CD compared 
to the general population, and the reason for such a 
difference has not been completely understood, thus 
limiting physicians’ interventional capabilities.
The aim of the present study was to compare the 
effectiveness of a multidisciplinary SCP in patients 
with and without CD and to explore the factors related 
to quitting failure in patients with CD.
METHODS
We performed a retrospective, observational, single-
centre, cohort study of active smokers who entered 
the outpatient multi-disciplinary SCP of the Luigi 
Sacco University Hospital of Milan, Italy, from 
January 2017 through January 2019. All patients 
entering the SCP were consecutively enrolled, and 
no strict eligibility criteria were applied to reflect real-
world practice conditions. The study sample included 
patients affected by CD who had been referred to our 
SCP by our Division of Gastroenterology. The study 
was approved by the local ethics committee (2018/
ST/169), conducted following the principles of the 
Declaration of Helsinki 1975 and written informed 
consent was obtained from all patients. Due to the 
retrospective nature of the study, the investigators 
did not have any role in dosing the treatments or in 
monitoring the exhaled carbon monoxide (CO) levels. 
All procedures were conducted following the local 
standard operating procedures in accordance with the 
principles of good clinical practice.
At baseline, sociodemographic and clinical 
characteristics were collected. A psychiatrist and 
a psychologist assessed the level of anxiety and 
depression by means of the Brief Psychiatric Rating 
Scale (BPRS)23, the motivation-to-quit score24 and 
nicotine dependence with the Fagerström test25,26. A 
pulmonologist monitored the exhaled CO by means 
of a portable analyser (EC50 Smokerlyser Bedfont 
Instruments; Kent, UK), and was responsible for the 
patients’ clinical and pharmacological management. 
Patients were followed up for 12 months during which 
they attended group psychological counselling once a 
week for the first month and were clinically reassessed 
by the pulmonologist on the 3rd, 6th and 12th month. 
Suitable patients were also prescribed pharmacological 
therapy with either varenicline27 or nicotine replacement 
therapy (NRT) through electronic nicotine delivery 
systems or nicotine transdermal patches28, according 
to clinical and smoking history, psychiatric evaluation 
and taking into account drug interactions with 
patients’ chronic therapy. Every visit consisted of a 
clinical assessment, and a pharmacological adjustment 
if considered necessary by the treating physician. 
Treatment compliance, together with exhaled CO, were 
also checked. We decided to consider a value of 6.5 ppm 
CO as the cut-off at every check-point to define a quitter 
as this value has been demonstrated to have satisfactory 
specificity and sensitivity to distinguish patients exposed 
to tobacco smoke29. A quitter was thus defined as a 
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patient with an exhaled CO value of ≤6.5 ppm at every 
follow-up visit (i.e. after 3, 6 and 12 months)29. During 
the follow-up period, patients were engaged in single 
and group meetings with both the psychiatrist and the 
psychologist, before being examined by the physician. 
Psychological and motivation-to-quit counselling and 
support were provided at each visit, based both on an 
individual and group therapeutic approach, guided by 
the psychologist.
Statistical analysis 
Statistical analysis was performed with SPSS version 
11.5 (SPSS Inc Chicago IL, USA). Variables were 
expressed as median and interquartile range (IQR) 
or means with standard deviation (SD), according 
to their distribution assessed with the Shapiro-Wilk 
test. Student’s t-test for independent groups, chi-
squared, Mann-Whitney or exact Fisher’s tests were 
used to compare patients with and without CD, or 
quitters and non-quitters, as appropriate. Relationships 
between variables were assessed by means of linear 
regression analysis. Tests were two-sided and statistical 
significance was set at p<0.05. The STROBE reporting 
checklist was applied to describe and discuss the results. 
RESULTS
A total of 158 patients were enrolled in the study 
(62% males). Twenty-two were lost to follow-up at the 
end of the study: 5 patients had an acute respiratory 
failure leading to hospitalization, 10 patients left the 
program due to working issues, 5 patients underwent 
major cardiac surgery, and two moved to another city. 
In all, 136 patients (58.1% males; mean age 55 years, 
SD=11) formed the study sample. Patients had smoked 
a median of 40 (IQR: 30–50) pack-years and had a 
high level of dependence on nicotine, while 34.6% 
reported a previous attempt to quit (Table 1). Twenty-
seven patients (19.8%) had CD, with a median age 
at diagnosis of 40 years (IQR: 29–52); demographic 
parameters, education level, Charlson index30, smoke 
history, and Fagerström score did not differ in patients 
with and without CD (Table 1). At baseline, patients 
with CD had a significantly higher BPRS (median: 27, 
IQR: 22–32; vs 25 and 22–28.5; p=0.03), and a lower 
motivation-to-quit score (median: 10, IQR: 9–13; vs 
14 and 12–15; p<0.001) (Table 1). 
Table 1. Baseline patients’ demographic and clinical characteristics. Data are reported for the whole study 
sample and for patients with and without Crohn’s disease (CD) 
Characteristics Whole sample 
(N=136 )
No CD 
(N=109 ), a
CD 
(N=27 ), b
p 
(a vs b)
Demographic features
Males, n (%) 79 (58.1) 63 (57.8) 16 (59) 0.535 χ2
Age (years), mean (SD) 54.6 (10.8) 55 (10.8) 52.9 (11) 0.789 t-test
Education level
Primary school, n (%) 8 (5.9) 7 (7.4) 1 (4.2)  
Secondary school, n (%) 31 (22.8) 25 (26.6) 6 (25) 0.403 χ2
High school, n (%) 58 (42.6) 43 (45.7) 15 (62)  
College, n (%) 21 (15.4) 19 (20.2) 2 (8)
Smoking and health status  
Charlson index, median (IQR) 2.00 (1–3) 2 (1–3) 2 (1–2) 0.14 Mann-Whitney
BPRS, median (IQR) 25 (22–31) 25 (22–28.5) 27 (22–32) 0.03 Mann-Whitney
Age started smoking, median (IQR) 17 (15–20) 16 (14–20) 17 (15–18) 0.568 Mann-Whitney
Age at Crohn diagnosis, median (IQR) 40 (29–52) n/a 40 (29–52) n/a
Cigs smoked/day, median (IQR) 20 (15–23) 20 (15–25) 15 (10–20) 0.026 Mann-Whitney
Pack-years, median (IQR) 40 (30–50) 40 (30–50) 35 (30–45) 0.299 Mann-Whitney
Previously attempted to quit, n (%) 47 (34.6) 38 (34.9) 9 (33.3) 0.536 χ2
Exhaled CO (ppm), mean (SD) 17.6 (7.2) 17.8 (7.2) 16.5 (8) 0.983 t-test
Fagerström score, median (IQR) 8 (6–9) 8 (6-9) 8 (6–9) 0.907 Mann-Whitney
Motivation to quit score, median (IQR) 13 (12–15) 14 (12–15) 10 (9–13) <0.001 Mann-Whitney
Continued
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Study outcome
At the end of the follow-up, 44 (32.4%) patients quit 
smoking. The quitters among patients with CD were 
significantly less compared with patients without CD 
(14.8% vs 36.7%; p<0.022) (Figure 1). 
BPRS and motivation to quit
Compared with patients that quit at the end of the 
follow-up, patients that failed to quit had a significantly 
higher BPRS scale (27.8 vs 24.5; p=0.004) and tended 
to have a lower motivation-to-quit score (12.8 vs 13.7; 
p=0.062). The chance of smoking cessation was in 
general negatively associated with the BPRS scale 
(r=-0.256; p<0.003) and with the Fagerström score 
(r=-0.222; p=0.01). 
At baseline, quitters without CD had a significantly 
higher motivation-to-quit score compared with 
patients with CD (14.2 and 9.7; p=0.004) (Figure 
2). Patients without CD that quit smoking at the end 
of the follow-up had a significantly lower baseline 
BPRS score (24.1 and 27.4; p=0.044). The same was 
not true for patients with CD (Figure 2). 
Pharmacological treatment
The proportion of quitters and quitting failure in 
the whole study sample did not differ depending on 
the treatment (9.1% vs 9.8%; 31.8% vs 31.5%; 59.1% 
vs 58.7%; for no treatment, NRT and varenicline, 
respectively; p=0.992). 
No significant difference could be observed in the 
proportion of patients that received either no treatment, 
NRT or varenicline between patients with CD and the 
rest of the study sample (Table 1). Among patients with 
CD, the proportion of treated patients that quit at the 
end of the follow-up was less compared with patients 
without CD, for all treatment regimens (Figure 3).
Table 1. Continued
Characteristics Whole sample 
(N=136 )
No CD 
(N=109 ), a
CD 
(N=27 ), b
p 
(a vs b)
Pharmacological treatment
None, n (%) 13 (9.6) 10 (9.2) 3 (11.1) 0.498 χ2
Varenicline, n (%) 80 (58.8) 62 (56.9) 18 (66.7) 0.241 χ2
NRT, n (%) 43 (31.6) 37 (33.9) 6 (22.2) 0.174 χ2
Outcome
Quitters, n (%) 44 (32.4) 40 (36.7) 4 (14.8) 0.022 χ2
Significant differences are highlighted in bold.  BPRS: Brief Psychiatric Rating Scale. NRT: nicotine replacement therapy. SD: standard deviation. IQR: inter quartile range. Cigs: 
cigarettes.
Figure 1. Study outcome. Proportion of quitters in patients with Crohn’s disease (light blue) and without
Crohn’s disease (dark blue); data are presented in absolute values (patients) and percentage relative to the
whole study sample
CD: Crohn’s disease.
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DISCUSSION
The main findings of the present study can 
be summarized as follows: 1) compared with 
other participants, smokers with CD attending a 
multidisciplinary SCP had a significantly lower chance 
to succeed in quitting the smoking habit; 2) a higher 
proportion of smokers with CD are characterized 
by anxiety and depression, associated with a lower 
motivation to quit; and 3) compared with treated 
smokers without CD, patients with CD exposed to 
a pharmacological treatment appeared to have less 
success in quitting smoking at the end of the follow-
up.
Many studies strongly support the effectiveness 
of smoking cessation in modifying the course of CD, 
with significant reduction in risk of flare-ups, need for 
surgery5,6 and better response to immunomodulating 
therapy31. Twelve months after quitting, risk of CD 
exacerbations and need for immunosuppressive 
therapy in quitters were comparable to those of non-
Figure 2. Motivation to quit and BPRS distribution in patients with and without Crohn’s disease. The motivation
to quit and the BPRS scores are reported for quitters and non-quitters in patients with Crohn’s disease
(light blue striped and full columns, respectively) and without Crohn’s disease (dark blue striped and full 
columns, respectively)
Ns: not significant.
Figure 3. Treatment response in patients with and without Crohn’s disease. The absolute number and the
proportion of patients (percentage) that quit at the end of the follow-up period for each treatment regimen are
reported for patients with Crohn’s disease (light blue striped columns) and without Crohn’s disease (dark blue
striped columns)
CD: Crohn’s disease. NRT: nicotine replacement therapy.
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smokers and inferior to those of active smokers2. 
However, very few studies have evaluated the 
effectiveness of a multidisciplinary SCP in patients 
with Crohn’s disease. A previous interventional study 
by Cosnes et al.2 found lower quit rates among patients 
with CD compared with the general population 
(about 12%). A more recent multicentre prospective 
interventional study, TABACROHN32, reported higher 
success rates, with 23% of 408 active smokers with 
CD labelled as smoking-free after a median 9-month 
follow-up.
The low quit rate of smokers with CD found in our 
study, despite the adoption of multidisciplinary SCP, 
is comparable to data by Cosnes et al.2. The difference 
with TABACROHN32 may be partially due to very 
different demographic and clinical characteristics of 
the patients enrolled in the study. In fact, smokers with 
CD in the TABACROHN study had a median age of 41 
years (IQR: 32–48) and had a smoking history of 13 
(6–25) pack-years, while our patients with CD were 
older, and had, on average, a heavier smoking history. 
Moreover, our findings are difficult to compare with 
the study of Nunes et al.32, due to differences in both 
study definitions and the interventional strategies 
adopted. First, in the TABACROHN study, patients 
were defined as quitters after self-reporting being 
completely smoking-free for at least one week and 
were then moved to the relapse group if they had 
resumed smoking in the subsequent follow-up; at 
the time of the publication, quitters had a median 
of 9 months of smoking-free follow-up. Conversely, 
we defined patients as quitters after a 12-month 
smoking-free follow-up, checking the exhaled CO to 
confirm the cessation of smoking habit. Second, in the 
TABACROHN study the smoking cessation strategy 
varied according to each centre’s clinical practice, 
with only 63% of the patients that were willing to 
quit assisted by a non-gastroenterologist physician 
(mostly a pulmonologist), and only 12% of patients 
having received pharmacological therapy32.
To date, factors associated with a low success of 
SCPs in patients with CD are still mostly undefined. 
The interventional study by Cosnes et al.2 found 
that the physician in-charge, previous intestinal 
resections, high socioeconomic status and use of 
oral contraceptives were independent predictors 
of smoking cessation, while other demographic 
characteristics, disease duration and smoking history 
were not significantly associated with the program’s 
outcome2. A survey conducted in 2001 showed 
similar attitude towards smoking cessation between 
smokers with and without CD, suggesting that factors 
not directly related to CD were more important in 
the willingness to quit33. In the TABACROHN 
study, no predictor of quit smoking was found, but 
good cessation rates in spite of inhomogeneous 
pharmacological support and involvement of experts 
suggest that counselling and the patient–physician 
relationship were the most effective tools to promote 
smoking cessation32. To our knowledge, this is the first 
study that found a lower quit smoking rate together 
with a higher incidence of anxiety and depression 
in patients with CD, confirming the importance of 
patients’ psychological burden reported in previous 
literature4.
Epidemiological data show that a significant 
percentage of patients with IBDs are affected by 
depression and/or anxiety disorders, particularly those 
with active disease34. On the other hand, smokers with 
depression are known to be less successful in attempts 
to quit35,36. In fact, nicotine intake improves depressive 
symptoms by modulating the stress response mediated 
by nicotine acetylcholine receptors, thus influencing 
a wide range of neurotransmitters, including 5-HT, 
dopamine, GABA, and glutamate. Accordingly, 
smoking cessation has been shown to precipitate 
depressive symptoms37. We thus hypothesize that the 
lower efficacy of a multidisciplinary SCP in patients 
with CD may be secondary to a higher prevalence of 
anxiety and depression34, which may drive increased 
nicotine consumption and expose patients to a greater 
risk of symptoms worsening after withdrawal35. This 
hypothesis is corroborated by our finding that the 
BPRS score at baseline was negatively correlated with 
a successful outcome after an SCP.
Differently from previous reports30, the majority 
of the patients participating to our study (>90%) 
were given a pharmacological treatment for smoking 
cessation, despite the absence of healthcare cost 
coverage for both varenicline and NRT; this may 
suggest quite a high motivation for quitting the 
smoking habit in patients enrolled in our SCP. 
Although the proportion of patients treated with 
either therapy, in the CD and non-CD groups, were 
not significantly different, in the present study each 
pharmacological treatment appeared to be less 
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efficacious in patients with CD who tended to have 
much lower quitting rates both with varenicline 
and NRT. The latter finding might be explained 
by a reduced adherence to pharmacotherapy for 
smoking cessation38, which may be more frequent in 
patients with CD, already exposed to a higher daily 
medication burden. However, the adherence to the 
pharmacological therapies introduced during the 
SCP could not be assessed retrospectively, and this 
represents a limitation of the study.
Limitations
We are aware that the present study has other 
important limitations that should be highlighted. 
The number of patients affected by CD is limited, 
reducing the statistical power and preventing us from 
making a statistical comparison of demographic and 
clinical characteristics between quitters and non-
quitters within the CD group. This limited our ability 
to investigate factors that may be related to smoking 
cessation in these particular group of patients. Our 
findings should be therefore validated and further 
explored by prospective studies involving a larger 
population of patients with CD. Nonetheless, the 
studied CD population may not reflect the proportion 
normally found in smoking cessation clinics, but is 
due to the structure of our teaching hospital and 
to the local standard procedures; the study is thus 
characterized by a selection and referral bias, making 
the generalizability of the results less expected. 
The availability and reimbursement of NRTs and 
varenicline may also vary from country to country, 
being an important confounding factor when 
comparing our results with other studies.
Moreover, the duration of the follow-up could 
be ideally longer than 12 months to confirm the 
long-term effectiveness of SCP and the incidence 
of smoking relapse; however, 12 months appears to 
be the most common follow-up duration in studies 
included in a Cochrane review investigating the role 
of physician advice in smoking cessation21.
CONCLUSIONS
In a population of smokers attending a multidisciplinary 
SCP, the success in quitting cigarette smoking was 
less likely in patients with CD; we also found that 
patients with CD had a higher prevalence of anxiety 
and depression, associated with a lower motivation 
to quit; we speculate that these psychological traits 
might have a role in jeopardizing the efficacy of the 
pharmacological treatments proposed for smoking 
cessation.
In view of the importance represented by quitting 
the smoking habit in patients with CD, we suggest 
here some interventions that should prove useful to 
improve disease control and patients’ disability: 1) 
primary prevention programmes to increase awareness 
of the role of smoking in CD, in consideration of 
widespread lack of knowledge about this topic in 
patients14; 2) psychological issue recognition and 
personalized counselling in CD smokers, due to high 
incidence of anxiety and depression in this population 
and its link to smoking; and 3) facilitated access of 
smokers with CD to SCPs with expertise in CD, 
because of the specific challenges posed by smoking 
cessation in these patients.
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